H. Lundbeck A/S: Schizophrenia trials
The registry lists 30 Schizophrenia studies with H. Lundbeck A/S as lead sponsor. 0 are open to participants now and 10 have results posted.
Phase 1 5Phase 2 6Phase 3 17Phase 4 1No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant SchizophreniaTerminatedNCT03230864Phase 3Results posted
- Flexible-dose, Long-term Safety Study of Lu AF35700 in Adult Patients With SchizophreniaCompletedNCT02892422Phase 3Results posted
- Effect of Lu AF35700 in Patients With Treatment-resistant SchizophreniaCompletedNCT02717195Phase 3Results posted
- Positron Emission Tomography (PET) Study Investigating Dopamine and Serotonin Receptor Occupancy After Multiple Oral Dosing of Lu AF35700CompletedNCT02333487Phase 1Results posted
- Aripiprazole Once-monthly in Patients With SchizophreniaCompletedNCT01959035Phase 3Results posted
- Brexpiprazole in Patients With SchizophreniaCompletedNCT01810783Phase 3Results posted
- Brexpiprazole in Patients With Acute SchizophreniaCompletedNCT01810380Phase 3Results posted
- Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With SchizophreniaCompletedNCT01795547Phase 3Results posted
- Study of the Safety, Tolerability, and Pharmacokinetics of Once Weekly Zicronapine in Patients With SchizophreniaCompletedNCT01377233Phase 2Results posted
- Safety Study of Sertindole Versus Risperidone Under Normal Conditions of UseCompletedNCT00856583Phase 3Results posted
- Flexible-dose Long-term Extension Study of Lu AF11167 in Patients With Schizophrenia With Prominent Negative SymptomsTerminatedNCT03929497Phase 2
- Study With Lu AF11167 for the Treatment of Negative Symptoms in Patients With SchizophreniaTerminatedNCT03793712Phase 2
- Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective DisorderCompletedNCT02901587Phase 1
- Comparison of the Effectiveness of Brexpiprazole With That of RisperidoneWithdrawnNCT02758067Phase 3
- Pharmacokinetic Properties of Various Modified Release Tablet Formulations of Lu AF11167CompletedNCT02260830Phase 1
- Safety and Tolerability Study of Lu AF35700 After Repeated Dosing in Patients With SchizophreniaCompletedNCT02202226Phase 1
- Safety and Tolerability Study of Lu AF11167 After Repeated Dosing in Patients With SchizophreniaCompletedNCT02202213Phase 1
- Real Life Assessment of Abilify MaintenaTerminatedNCT02131415
- Safety and Efficacy of Zicronapine in Patients With SchizophreniaCompletedNCT01295372Phase 3
- Sertindole in Asian Patients With SchizophreniaCompletedNCT00864045Phase 3
- Bifeprunox Extension to Extension Study in Patients With SchizophreniaTerminatedNCT00861497Phase 3
- Efficacy Study Exploring the Effect of Lu AE58054 as Augmentation Therapy in Patients With SchizophreniaCompletedNCT00810667Phase 2
- Efficacy of Lu 31-130 in Patients With SchizophreniaCompletedNCT00770744Phase 2
- Efficacy of Lu 31-130 in Patients With SchizophreniaCompletedNCT00768326Phase 2
- Safety Study of an Antipsychotic, Sertindole, to Treat SchizophreniaCompletedNCT00763438Phase 4
- Study on Metabolic Parameters of Sertindole in Patients With SchizophreniaCompletedNCT00759460Phase 3
- Exploratory Cognition Study of Sertindole in Patients With SchizophreniaCompletedNCT00759421Phase 3
- Efficacy of Bifeprunox in Patients With SchizophreniaTerminatedNCT00704509Phase 3
- Efficacy of Bifeprunox in Patients With SchizophreniaTerminatedNCT00658645Phase 3
- Efficacy Study Exploring the Effects on Cognition of Sertindole Versus Comparator in Patients With SchizophreniaCompletedNCT00654706Phase 3